重视胰腺癌的新辅助治疗  

The important role of neoadjuvant therapy in pancreatic cancer

作　　者：张太平[1] 邱江东 Zhang Taiping;Qiu Jiangdong(Department of General Surgery,Peking Union Medical College Hospital,Chinese Academy of Medical Sciences and Peking Union Medical College,Beijing 100730,China)

机构地区：[1]中国医学科学院北京协和医院基本外科,北京100730

出　　处：《中华肝胆外科杂志》2020年第9期641-644,共4页Chinese Journal of Hepatobiliary Surgery

摘　　要：胰腺癌是高度恶性的消化系统肿瘤,手术技术的进步未能明显改善患者预后。随着多学科诊疗理念的普及,新辅助治疗在胰腺癌中的地位逐渐凸显。新辅助治疗旨在缩小肿瘤,消除微转移病灶,进而提高R0切除率,减少复发转移。由于胰腺癌独特的肿瘤微环境,其对放疗、化疗敏感性较低,新辅助治疗并非对所有胰腺癌患者有效,且在患者选择、方案制定、治疗后再评估等方面仍存在诸多争议,临床应用仍不十分成熟。当前应重视新辅助治疗在胰腺癌中的作用,鼓励开展高质量临床研究,充分发挥多学科诊疗优势,为胰腺癌患者制定个体化新辅助治疗方案,以进一步提升患者预后。Pancreatic cancer is a highly aggressive tumor in the digestive system,and the progress in surgical technique hasn’t improved patients’prognosis significantly for many years.As the popularization of multidisciplinary team,the role of neoadjuvant therapy has been highlighted in pancreatic cancer.The aim of neoadjuvant therapy is to reduce the tumor size and eliminate micro-metastasis,so as to increase the R0 resection rate and decrease recurrence and metastasis.Due to the unique tumor microenvironment,pancreatic cancer is not sensitive to chemotherapy and radiotherapy.So neoadjuvant therapy is not effective for all patients,and controversy still exists regarding the patients selection,therapeutic regimen,re-evaluation after neoadjuvant therapy,etc.The application of neoadjuvant therapy is not very mature.At present,we should pay more attention to the role of neoadjuvant therapy in pancreatic cancer.More high-quality clinical researches are urgently needed,and multidisciplinary team should be applied to make personalized treatment strategy in order to improve the prognosis of patients with pancreatic cancer.

关 键 词：胰腺肿瘤 新辅助治疗 临床研究 多学科诊疗 

分 类 号：R735.9[医药卫生—肿瘤]